| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 29 | 2025 | 595 | 6.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2025 | 414 | 3.970 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2024 | 337 | 3.490 |
Why?
|
| Uterine Cervical Neoplasms | 15 | 2025 | 301 | 2.460 |
Why?
|
| Endometrial Neoplasms | 14 | 2024 | 189 | 2.010 |
Why?
|
| Bevacizumab | 11 | 2025 | 106 | 1.700 |
Why?
|
| Indazoles | 5 | 2025 | 18 | 1.600 |
Why?
|
| Immunoconjugates | 3 | 2023 | 21 | 1.550 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2022 | 33 | 1.450 |
Why?
|
| Paclitaxel | 11 | 2021 | 191 | 1.430 |
Why?
|
| Female | 65 | 2025 | 15472 | 1.310 |
Why?
|
| Piperidines | 3 | 2025 | 48 | 1.280 |
Why?
|
| Adenocarcinoma | 8 | 2018 | 300 | 1.190 |
Why?
|
| Middle Aged | 44 | 2025 | 7310 | 1.110 |
Why?
|
| Genital Neoplasms, Female | 5 | 2022 | 67 | 1.090 |
Why?
|
| Adult | 39 | 2025 | 7922 | 1.050 |
Why?
|
| Aged | 35 | 2025 | 5525 | 1.040 |
Why?
|
| Antineoplastic Agents | 6 | 2024 | 681 | 1.040 |
Why?
|
| Hysterectomy | 9 | 2020 | 86 | 1.020 |
Why?
|
| Humans | 68 | 2025 | 28585 | 0.980 |
Why?
|
| Yttrium Radioisotopes | 1 | 2025 | 4 | 0.910 |
Why?
|
| Aged, 80 and over | 19 | 2025 | 2045 | 0.830 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2020 | 41 | 0.810 |
Why?
|
| Salvage Therapy | 3 | 2018 | 35 | 0.690 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2018 | 163 | 0.680 |
Why?
|
| Sulfonamides | 2 | 2018 | 73 | 0.680 |
Why?
|
| Triazoles | 3 | 2024 | 16 | 0.660 |
Why?
|
| Hydrazines | 3 | 2024 | 13 | 0.660 |
Why?
|
| Pyrimidines | 2 | 2018 | 128 | 0.650 |
Why?
|
| Retrospective Studies | 21 | 2020 | 2612 | 0.650 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2024 | 104 | 0.640 |
Why?
|
| Chemoradiotherapy | 5 | 2025 | 44 | 0.600 |
Why?
|
| Maintenance Chemotherapy | 5 | 2025 | 18 | 0.590 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 42 | 0.560 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 67 | 0.540 |
Why?
|
| Lymph Nodes | 3 | 2018 | 103 | 0.520 |
Why?
|
| Vulvar Neoplasms | 3 | 2016 | 25 | 0.510 |
Why?
|
| Sarcoma | 1 | 2016 | 29 | 0.480 |
Why?
|
| Neoplasm Staging | 15 | 2025 | 478 | 0.480 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2025 | 170 | 0.470 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 71 | 0.470 |
Why?
|
| Cisplatin | 8 | 2025 | 183 | 0.450 |
Why?
|
| Survival Rate | 12 | 2021 | 431 | 0.440 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2025 | 53 | 0.430 |
Why?
|
| Pyridines | 2 | 2025 | 108 | 0.430 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2025 | 38 | 0.420 |
Why?
|
| Brachytherapy | 5 | 2025 | 51 | 0.390 |
Why?
|
| CA-125 Antigen | 3 | 2008 | 19 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2025 | 147 | 0.380 |
Why?
|
| Lymphatic Metastasis | 5 | 2020 | 126 | 0.350 |
Why?
|
| Peritoneal Neoplasms | 2 | 2025 | 80 | 0.350 |
Why?
|
| Lymph Node Excision | 5 | 2020 | 101 | 0.320 |
Why?
|
| Disease-Free Survival | 8 | 2020 | 236 | 0.320 |
Why?
|
| Quality of Life | 3 | 2025 | 504 | 0.310 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 1026 | 0.310 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2020 | 13 | 0.300 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 216 | 0.290 |
Why?
|
| Neoplasms | 3 | 2024 | 857 | 0.290 |
Why?
|
| Prognosis | 7 | 2020 | 807 | 0.290 |
Why?
|
| Maximum Tolerated Dose | 2 | 2025 | 32 | 0.280 |
Why?
|
| Biological Availability | 2 | 2024 | 44 | 0.280 |
Why?
|
| Incidental Findings | 2 | 2018 | 13 | 0.260 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2021 | 108 | 0.250 |
Why?
|
| Anastomosis, Surgical | 1 | 2006 | 38 | 0.250 |
Why?
|
| Platinum | 2 | 2023 | 18 | 0.240 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 72 | 0.240 |
Why?
|
| Vaginal Neoplasms | 1 | 2025 | 12 | 0.230 |
Why?
|
| Double-Blind Method | 3 | 2024 | 421 | 0.230 |
Why?
|
| CD47 Antigen | 1 | 2025 | 4 | 0.230 |
Why?
|
| CD40 Antigens | 1 | 2025 | 14 | 0.230 |
Why?
|
| Cadherins | 1 | 2025 | 24 | 0.230 |
Why?
|
| Robotics | 3 | 2010 | 43 | 0.230 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 36 | 0.220 |
Why?
|
| Radiopharmaceuticals | 1 | 2025 | 73 | 0.220 |
Why?
|
| Viral Vaccines | 1 | 2023 | 14 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 113 | 0.210 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 164 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2021 | 2402 | 0.190 |
Why?
|
| Carboplatin | 5 | 2021 | 112 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2022 | 273 | 0.180 |
Why?
|
| Taxoids | 3 | 2013 | 37 | 0.180 |
Why?
|
| Risk Factors | 5 | 2020 | 2111 | 0.170 |
Why?
|
| Electrocardiography | 1 | 2022 | 394 | 0.170 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 25 | 0.170 |
Why?
|
| Withholding Treatment | 1 | 2020 | 20 | 0.160 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2010 | 33 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 25 | 0.150 |
Why?
|
| Angiopoietin-2 | 1 | 2019 | 10 | 0.150 |
Why?
|
| Drug Approval | 1 | 2019 | 11 | 0.150 |
Why?
|
| Angiopoietin-1 | 1 | 2019 | 8 | 0.150 |
Why?
|
| Piperazines | 1 | 2019 | 50 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 57 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 45 | 0.150 |
Why?
|
| Hypoalbuminemia | 1 | 2018 | 3 | 0.150 |
Why?
|
| Texas | 2 | 2016 | 138 | 0.150 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2018 | 12 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2019 | 84 | 0.150 |
Why?
|
| Fistula | 1 | 2018 | 17 | 0.150 |
Why?
|
| Placebos | 1 | 2018 | 48 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 148 | 0.140 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 12 | 0.140 |
Why?
|
| Male | 3 | 2025 | 13772 | 0.130 |
Why?
|
| Colostomy | 2 | 2008 | 8 | 0.130 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2017 | 3 | 0.130 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2017 | 6 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 54 | 0.130 |
Why?
|
| Mutation | 1 | 2021 | 864 | 0.130 |
Why?
|
| Carcinoma | 1 | 2017 | 74 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 26 | 0.120 |
Why?
|
| Transportation of Patients | 1 | 2016 | 29 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 389 | 0.120 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2015 | 6 | 0.120 |
Why?
|
| Thiosemicarbazones | 2 | 2025 | 5 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2024 | 21 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2023 | 1272 | 0.110 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2014 | 2 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 16 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2014 | 68 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 410 | 0.110 |
Why?
|
| Patient Selection | 1 | 2014 | 149 | 0.100 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 149 | 0.100 |
Why?
|
| Rectum | 2 | 2019 | 50 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 302 | 0.100 |
Why?
|
| United States | 1 | 2019 | 2201 | 0.100 |
Why?
|
| Conization | 1 | 2011 | 11 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 288 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 302 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2020 | 893 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 333 | 0.080 |
Why?
|
| Endometrium | 2 | 2022 | 39 | 0.080 |
Why?
|
| Platinum Compounds | 1 | 2009 | 14 | 0.080 |
Why?
|
| Outpatients | 1 | 2009 | 44 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2008 | 19 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 24 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 47 | 0.070 |
Why?
|
| Surgical Stomas | 1 | 2008 | 6 | 0.070 |
Why?
|
| Ulcer | 2 | 2019 | 5 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2008 | 65 | 0.070 |
Why?
|
| Colonic Diseases | 1 | 2008 | 10 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 77 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 270 | 0.070 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2007 | 35 | 0.070 |
Why?
|
| Topotecan | 2 | 2020 | 12 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 194 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2007 | 58 | 0.060 |
Why?
|
| Colon, Sigmoid | 1 | 2006 | 1 | 0.060 |
Why?
|
| Ileostomy | 1 | 2006 | 6 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 357 | 0.060 |
Why?
|
| Thiadiazines | 1 | 2025 | 1 | 0.060 |
Why?
|
| Rectovaginal Fistula | 2 | 2019 | 4 | 0.060 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2025 | 5 | 0.060 |
Why?
|
| Gynecology | 2 | 2017 | 60 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 38 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 47 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2025 | 37 | 0.060 |
Why?
|
| Young Adult | 4 | 2015 | 2804 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2008 | 301 | 0.060 |
Why?
|
| Medical Oncology | 2 | 2017 | 97 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 190 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2019 | 209 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2024 | 4 | 0.050 |
Why?
|
| Tablets | 1 | 2024 | 6 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2024 | 95 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 233 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 137 | 0.050 |
Why?
|
| Fasting | 1 | 2024 | 90 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 611 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 226 | 0.050 |
Why?
|
| NEDD8 Protein | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cervix Uteri | 1 | 2022 | 65 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 186 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 251 | 0.040 |
Why?
|
| Heart | 1 | 2022 | 224 | 0.040 |
Why?
|
| Epothilones | 1 | 2021 | 5 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 14 | 0.040 |
Why?
|
| Indoles | 1 | 2022 | 110 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 25 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 76 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2019 | 2 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2019 | 15 | 0.040 |
Why?
|
| Rectal Diseases | 1 | 2019 | 10 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 32 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 105 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 90 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 224 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 110 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 66 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 137 | 0.040 |
Why?
|
| Uterine Diseases | 1 | 2018 | 2 | 0.040 |
Why?
|
| Uterine Hemorrhage | 1 | 2018 | 9 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 524 | 0.040 |
Why?
|
| Endometrial Hyperplasia | 1 | 2018 | 6 | 0.040 |
Why?
|
| Palliative Care | 2 | 2009 | 84 | 0.030 |
Why?
|
| Reoviridae | 1 | 2017 | 2 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 3 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 7 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 41 | 0.030 |
Why?
|
| Stretchers | 1 | 2016 | 1 | 0.030 |
Why?
|
| Lacerations | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2017 | 91 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2016 | 60 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 54 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 104 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 164 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 26 | 0.030 |
Why?
|
| Adolescent | 2 | 2014 | 3165 | 0.030 |
Why?
|
| Adnexa Uteri | 1 | 2014 | 2 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 31 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 86 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 89 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 734 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 41 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 994 | 0.020 |
Why?
|
| Polyglutamic Acid | 1 | 2012 | 3 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2012 | 4 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 622 | 0.020 |
Why?
|
| Laparotomy | 1 | 2012 | 35 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 311 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 475 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 671 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 1219 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 17 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 33 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 75 | 0.020 |
Why?
|
| Pelvis | 1 | 2010 | 38 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 43 | 0.020 |
Why?
|
| Bartholin's Glands | 1 | 2009 | 1 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 11 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 35 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 34 | 0.020 |
Why?
|
| Microdissection | 1 | 2009 | 15 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 2009 | 38 | 0.020 |
Why?
|
| Aorta | 1 | 2010 | 124 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2009 | 10 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 465 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 26 | 0.020 |
Why?
|
| Alleles | 1 | 2009 | 354 | 0.020 |
Why?
|
| Prolapse | 1 | 2008 | 3 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 194 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 682 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 147 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2009 | 156 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 732 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 10583 | 0.010 |
Why?
|